Pulmonary Arterial Hypertension Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034

All the vital news, analysis, and commentary curated by our industry experts.

$17995

Buy Report

Published: June 27, 2025 Report Code: GDHC318PIDR-7M-ST

Report Overview
Key Players
Table of Contents
Table
Figures

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Pulmonary Arterial Hypertension market through 2034.

GlobalData estimated that drug sales for PAH in 2024 were approximately $7.65 billion across the 7MM. With an estimated $5.83 billion in drug sales in 2024, the US dominated the PAH market, contributing 76.3% of the sales in the 7MM. This high market share is primarily due to the large PAH prevalent population and high price of branded drugs in the US compared to the 5EU and Japan. GlobalData anticipates that the PAH market will grow to be worth approximately $9.35 billion by 2034, at a compound annual growth rate (CAGR) of 2.0%. The US is expected to maintain its position as the market leader in 2034.
The major drivers of growth in the PAH market during the forecast period include the following:
• The number of total prevalent cases of PAH in the US, France, and the UK is expected to increase during the forecast period in line with population growth, therefore increasing the total addressable patient population. As populations age and diagnostic awareness improves, more patients are being identified and treated for PAH. Expanded screening in high-risk groups and longer patient survival are contributing to a growing prevalence pool, particularly in the US.
• Increased use of combination therapy following the positive outcomes from the AMBITION trial has boosted PAH sales due to higher treatment costs of drug combinations. The AMBITION trial established the superiority of initial dual therapy over monotherapy, prompting widespread adoption of endothelin receptor antagonist (ERA) + phosphodiesterase-5 inhibitor (PDE5i) combinations. As dual and triple regimens become standard, the use of multiple drugs raises treatment costs and overall market value.
• The increased usage of Merck’s first-in-class Winrevair (sotatercept) and launch of pipeline therapies including Liquidia Corp’s Yutrepia (treprostinil) and Tenax Therapeutics’ imatinib will boost PAH sales. Winrevair is the first approved disease-modifying agent for PAH and is expected to see broad uptake across patient segments. New launches like Yutrepia, with improved inhaled delivery, and oral imatinib, targeting vascular remodeling, will expand treatment options and support continued market growth.
• The major barriers to growth in the PAH market during the forecast period will include the following:
• Low disease awareness among patients and physicians will lead to a lower disease diagnosis rate and delayed diagnosis. Many early PAH symptoms are nonspecific and often misattributed to more common conditions, resulting in under-referral and diagnostic delays. Limited recognition of risk factors and insufficient screening outside of specialist centers continue to hinder timely treatment initiation.

Scope

Overview of pulmonary arterial hypertension, including epidemiology, symptoms, diagnosis, and disease management.

Annualized pulmonary arterial hypertension therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2024 to 2034.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the pulmonary arterial hypertension therapeutics market.

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for pulmonary arterial hypertension treatment. The most promising candidates in late-stage development are profiled.

Analysis of the current and future market competition in the global pulmonary arterial hypertension therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the 7MM PAH therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM PAH therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

AbbVie Inc
Acceleron Pharma Inc
Actelion
Amgen Inc
Bayer AG
Bristol Myers Squibb
Eli Lilly and Co
Entera Bio Ltd
Gilead Sciences Inc
GlaxoSmithKline
Johnson & Johnson
Merck & Co Inc
Novartis International AG
Pfizer Inc
Roche Holding AG
Sanofi
Teva Pharmaceutical Industries Ltd
UCB S.A.

1 Pulmonary Arterial Hypertension: Executive Summary

1.1 Pulmonary arterial hypertension therapeutics market will grow to $9.34 billion by 2034

1.2 Winrevair is reshaping the PAH treatment landscape following its commercial launch

1.3 Persistent unmet needs underscore opportunity for innovation across the PAH landscape

1.4 Late-stage pipeline advances offer strategic additions across the PAH treatment landscape

1.5 What do physicians think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification or staging systems

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 Forecast methodology

4.4.1 Sources

4.4.2 Forecast assumptions and methods

4.4.3 Forecast assumptions and methods: diagnosed incident cases and diagnosed prevalent cases of PAH

4.4.4 7MM

4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of PAH by NYHA functional class

4.4.6 US

4.4.7 Forecast assumptions and methods: diagnosed prevalent cases of PAH by comorbidity

4.4.8 US

4.5 Epidemiological forecast for PAH (2024–34)

4.5.1 Diagnosed incident cases of PAH

4.5.2 Age-specific diagnosed incident cases of PAH

4.5.3 Sex-specific diagnosed incident cases of PAH

4.5.4 Diagnosed prevalent cases of PAH

4.5.5 Age-specific diagnosed prevalent cases of PAH

4.5.6 Sex-specific diagnosed prevalent cases of PAH

4.5.7 Diagnosed prevalent cases of PAH by NYHA functional class

4.5.8 Diagnosed prevalent cases of PAH by comorbidity

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 Limitations of the analysis

4.6.3 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview

5.2 US disease management

5.3 5EU disease management

5.4 Japan disease management

5.5 KOL insights on disease management

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Improved physician awareness and earlier diagnosis

7.3 Improved therapy convenience and reduced side effects

7.4 Disease-modifying therapies

7.5 Improved clinical trial design

8 R&D Strategies

8.1 Overview

8.1.1 Disease-modifying mechanisms and novel targets

8.1.2 Innovations in drug delivery and combination therapy

8.1.3 Strategic collaborations and targeted development

8.2 Clinical trials design

8.2.1 Advancements in PAH endpoints

8.2.2 Patient population selection

8.2.3 Use of surrogate biomarkers

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

12.1 Global markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting methodology

13.4 Primary research – KOLs interviewed for this report

13.4.1 KOLs

13.5 Primary research – prescriber survey

13.6 About the authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Vice President of Disease Intelligence and Epidemiology

13.6.4 Global Head of Pharma Research, Analysis, and Competitive Intelligence

About GlobalData

Table

Table 1: PAH: key metrics in the 7MM

Table 2: NYHA/WHO functional class (FC)

Table 3: Risk factors and comorbidities for PAH

Table 4: Treatment guidelines for PAH

Table 5: Top 10 deals by value, 2020–25

Table 6: PAH market – global drivers and barriers, 2024–34

Table 7: Key events impacting sales for PAH in the US, 2024–34

Table 8: PAH market – drivers and barriers in the US, 2024–34

Table 9: Key events impacting sales for PAH in the 5EU, 2024–34

Table 10: PAH market – drivers and barriers in the 5EU, 2024–34

Table 11: Key events impacting sales for PAH in Japan, 2024–34

Table 12: PAH market – drivers and barriers in Japan, 2024–34

Table 13: High-prescribing physicians (non-KOLs) surveyed, by country

Figures

Figure 1: Global sales forecast by country for PAH in 2024 and 2034

Figure 2: Analysis of the company portfolio gap in PAH during the forecast period

Figure 3: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of PAH during the forecast period

Figure 4: Target pathways of the currently marketed drugs for PAH

Figure 5: 7MM, diagnosed incidence of PAH (cases per 100,000 population), both sexes, all ages, 2024

Figure 6: 7MM, diagnosed prevalence of PAH (%), both sexes, all ages, 2024

Figure 7: 7MM, sources used and not used to forecast the diagnosed incident cases of PAH

Figure 8: 7MM, sources used and not used to forecast the diagnosed prevalent cases of PAH

Figure 9: 7MM, sources used and not used to forecast the diagnosed prevalent cases of PAH by NYHA functional classes in the 7MM

Figure 10: 7MM, sources used to forecast the diagnosed prevalent cases of PAH by comorbidities (CTD, CHD, and scleroderma)

Figure 11: 7MM, sources used to forecast the diagnosed prevalent cases of PAH by comorbidities (diabetes, COPD, and PH)

Figure 12: 7MM, diagnosed incident cases of PAH, N, both sexes, all ages, 2024

Figure 13: 7MM, diagnosed incident cases of PAH by age, N, women, 2024

Figure 14: 7MM, sex-specific diagnosed incident cases of PAH, N, all ages, 2024

Figure 15: 7MM, diagnosed prevalent cases of PAH, N, both sexes, all ages, 2024

Figure 16: 7MM, diagnosed prevalent cases of PAH by age, N, both sexes, 2024

Figure 17: 7MM, sex-specific diagnosed prevalent cases of PAH, N, all ages, 2024

Figure 18: 7MM, diagnosed prevalent cases of PAH by NYHA functional class, N, both sexes, all ages, 2024

Figure 19: 7MM, diagnosed prevalent cases of PAH by comorbidity, N, both sexes, all ages, 2024

Figure 20: Diagnostic approach to PAH

Figure 21: Unmet needs and opportunities in PAH

Figure 22: Overview of the development pipeline in PAH

Figure 23: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for PAH in the 7MM during the forecast period

Figure 24: Competitive assessment of the marketed and pipeline drugs benchmarked against the standard of care (SOC), Opsumit

Figure 25: Analysis of the company portfolio gap in PAH during the forecast period

Figure 26: Global (7MM) sales forecast by country for PAH in 2024 and 2034

Figure 27: Sales forecast by class for PAH in the US in 2024 and 2034

Figure 28: Sales forecast by class for PAH in the 5EU in 2024 and 2034

Figure 29: Sales forecast by class for PAH in Japan in 2024 and 2034

Pulmonary Arterial Hypertension Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 standard reports

Currency USD

Single User

$17,995

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Pulmonary Arterial Hypertension reports

Pharmaceuticals

New

Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…

Pharmaceuticals

New

IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive…

Pharmaceuticals

New

Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Pulmonary Arterial Hypertension Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 in real time.

Access a live Pulmonary Arterial Hypertension Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

Pulmonary Arterial Hypertension Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034

Scope

Reasons to Buy

Table of Contents

Table

Figures

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Related reports